Patents by Inventor Jennifer Venable

Jennifer Venable has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor of p38 MAP kinase
    Patent number: 11634406
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: April 25, 2023
    Assignee: RESPIVERT LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20210179584
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: June 17, 2021
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Inhibitor of p38 MAP kinase
    Patent number: 10815217
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: October 27, 2020
    Assignee: Respivert Ltd.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20190092752
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Application
    Filed: July 11, 2018
    Publication date: March 28, 2019
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Inhibitor of p38 map kinase
    Patent number: 10045980
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 14, 2018
    Assignee: Respivert Ltd
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20170182039
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Inventors: ALISTAIR IAN LONGSHAW, EUAN ALEXANDER FRASER FORDYCE, STUART THOMAS ONIONS, JOHN KING-UNDERWOOD, JENNIFER VENABLE
  • Inhibitor of p38 MAP kinase
    Patent number: 9624196
    Abstract: A compound of formula (XV): wherein R1 represents an amino group, a protected amino group or nitro group; or a salt thereof. The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 18, 2017
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20160368896
    Abstract: A compound of formula (XV): wherein R1 represents an amino group, a protected amino group or nitro group; or a salt thereof. The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 22, 2016
    Inventors: ALISTAIR IAN LONGSHAW, EUAN ALEXANDER FRASER FORDYCE, STUART THOMAS ONIONS, JOHN KING-UNDERWOOD, JENNIFER VENABLE
  • Inhibitor of p38 map kinase
    Patent number: 9447076
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 20, 2016
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20150232450
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Application
    Filed: February 13, 2015
    Publication date: August 20, 2015
    Inventors: ALISTAIR IAN LONGSHAW, EUAN ALEXANDER FRASER FORDYCE, STUART THOMAS ONIONS, JOHN KING-UNDERWOOD, JENNIFER VENABLE
  • Imidazole compounds
    Publication number: 20070265250
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: June 29, 2007
    Publication date: November 15, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
    Publication number: 20070244126
    Abstract: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 18, 2007
    Inventors: James Edwards, David Kindrachuk, Christopher Mapes, Daniel Pippel, Jennifer Venable
  • Imidazole compounds
    Publication number: 20070173512
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: February 8, 2007
    Publication date: July 26, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Imidazole compounds
    Publication number: 20070173513
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: February 8, 2007
    Publication date: July 26, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Imidazole compounds
    Publication number: 20070173509
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: February 8, 2007
    Publication date: July 26, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Imidazole compounds
    Publication number: 20070173510
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: February 8, 2007
    Publication date: July 26, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Imidazole compounds
    Publication number: 20070149541
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: February 8, 2007
    Publication date: June 28, 2007
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Imidazole compounds
    Publication number: 20050261309
    Abstract: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: March 24, 2005
    Publication date: November 24, 2005
    Inventors: Daniel Buzard, James Edwards, David Kindrachuk, Jennifer Venable
  • Quinoxaline compounds
    Publication number: 20050070527
    Abstract: Quinoxaline compounds, compositions, methods of making them, and methods of using them in leukocyte recruitment inhibition, in modulating an H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: September 29, 2004
    Publication date: March 31, 2005
    Inventors: James Edwards, Jennifer Venable
  • Benzoimidazole compounds
    Publication number: 20050070550
    Abstract: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
    Type: Application
    Filed: September 29, 2004
    Publication date: March 31, 2005
    Inventors: Kristen Arienti, J. Breitenbucher, Daniel Buzard, James Edwards, Michael Hack, Haripada Khatuya, David Kindrachuk, Alice Lee, Jennifer Venable